This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Acceleron (XLRN) Gets Orphan Drug Tag for ACE-1334 by FDA
by Zacks Equity Research
The FDA grants orphan drug designation to Acceleron's (XLRN) ACE-1334 for the treatment of patients with systemic sclerosis.
Amicus (FOLD) Initiates Rolling BLA Submission for AT-GAA
by Zacks Equity Research
Amicus (FOLD) initiates a rolling biologics license application (BLA) submission to the FDA for AT-GAA, for the treatment of late onset Pompe disease.
Verastem (VSTM) Begins Phase II Combo Study for Ovarian Cancer
by Zacks Equity Research
Verastem (VSTM) initiates phase II registration-directed study of VS-6766 and defactinib in patients with recurrent low-grade serous ovarian cancer.
Deciphera (DCPH) Ends Qinlock Second-Line GIST Study Enrollment
by Zacks Equity Research
Deciphera (DCPH) completes enrollment in the phase III study evaluating Qinlock in patients with second-line gastrointestinal stromal tumor.
ORIC Pharmaceuticals (ORIC) in Focus: Stock Moves 6.7% Higher
by Zacks Equity Research
ORIC Pharmaceuticals (ORIC) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
HorizonTherapeutics (HZNP) Rises YTD on Approvals & Buyouts
by Zacks Equity Research
Horizon Therapeutics (HZNP) expects continued strong growth for Krystexxa and Tepezza in 2021. It is making efforts to expand the label for its marketed drugs.
Eiger (EIGR) Gets FDA Approval for Zokinvyin Rare Diseases
by Zacks Equity Research
Eiger (EIGR) gets FDA approval for Zokinvy for the treatment of Hutchinson-Gilford Progeria Syndrome and processing-deficient Progeroid Laminopathies.
Horizon (HZNP) and Halozyme Ink Deal for ENHANZE Technology
by Zacks Equity Research
Horizon (HZNP) inks deal to get an exclusive access to Halozyme's ENHANZE drug delivery technology for subcutaneous formulation of medicines targeting IGF-1R.
Amgen (AMGN) Ends Deal With Cytokinetics for Heart Candidate
by Zacks Equity Research
Amgen (AMGN) will terminate the collaboration with Cytokinetics and transition development and commercialization rights for omecamtiv mecarbil and AMG 594 to the latter.
Novo Nordisk's (NVO) Phase IIIb Study Meets Primary Endpoint
by Zacks Equity Research
Novo Nordisk's (NVO) semaglutide 2.0 mg demonstrates superior reduction in HbA1c versus once-weekly semaglutide 1.0 mg in people with type II diabetes.
Alkermes (ALKS) Receives FDA CRL in Relation to ALKS 3831
by Zacks Equity Research
Alkermes (ALKS) gets a CRL by the FDA for ALKS 3831 for the treatment of adults with schizophrenia and bipolar I disorder.
Apellis' (APLS) Blood Disorder Drug Gets FDA's Priority Tag
by Zacks Equity Research
The FDA accepts Apeliis' (APLS) NDA for pegcetacoplanand and grants priority review for the treatment of paroxysmal nocturnal hemoglobinuria.
ASLAN Pharmaceuticals (ASLN) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
ASLAN Pharmaceuticals (ASLN) has been struggling lately, but the selling pressure may be coming to an end soon.
ASLAN Pharmaceuticals (ASLN) in Focus: Stock Moves 7% Higher
by Zacks Equity Research
ASLAN Pharmaceuticals (ASLN) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
ASLAN Pharmaceuticals Ltd. (ASLN) Upgraded to Buy: Here's Why
by Zacks Equity Research
ASLAN Pharmaceuticals Ltd. (ASLN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ASLAN Pharmaceuticals (ASLN) Looks Good: Stock Adds 8.7% in Session
by Zacks Equity Research
ASLAN Pharmaceuticals (ASLN) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
ASLAN Pharmaceuticals Ltd. (ASLN) Gains As Market Dips: What You Should Know
by Zacks Equity Research
ASLAN Pharmaceuticals Ltd. (ASLN) closed at $1.92 in the latest trading session, marking a +0.26% move from the prior day.
ASLAN Pharmaceuticals Ltd. (ASLN) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
ASLAN Pharmaceuticals Ltd. (ASLN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ASLAN Pharmaceuticals Ltd (ASLN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, ASLAN Pharmaceuticals Ltd (ASLN) closed at $1.65, marking a +0.61% move from the previous day.
Gilead (GILD) in Focus: Stock Moves 9.7% Higher
by Zacks Equity Research
Gilead (GILD) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
ASLAN Pharmaceuticals Ltd. (ASLN) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
ASLAN Pharmaceuticals Ltd. (ASLN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
ASLAN Pharmaceuticals Ltd. (ASLN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
ASLAN Pharmaceuticals Ltd. (ASLN) closed the most recent trading day at $2.17, moving +0.93% from the previous trading session.
Regeneron & Sanofi's sBLA for Dupixent Accepted by the FDA
by Zacks Equity Research
The FDA accepts Regeneron (REGN) and Sanofi's sBLA for Dupixent for Priority Review.
Has ASLAN Pharmaceuticals (ASLN) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (ASLN) Outperforming Other Medical Stocks This Year?
Alexion to Start Pivotal Study on Ultomiris for ALS in Q1
by Zacks Equity Research
Alexion (ALXN) plans to initiate a phase III study on Ultomiris (ravulizumab) to treat amyotrophic lateral sclerosis.